Form D · Pharmaceuticals
Supreme Pharmaceuticals Inc.
Toronto, A6 · CIK 0001622240
Offering snapshot reported Mar 17, 2017 · SEC filing
- Reported sold
- $370K Offering amount: $370K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 13, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2017 | Initial | $369,667 | No comparison | 1 | SEC filing |
| May 8, 2015 | Initial | $1,212,649 | No comparison | 27 | SEC filing |
| Feb 3, 2015 | Initial | $116,985 | No comparison | 3 | SEC filing |
| Nov 20, 2014 | Initial | $149,117 | No comparison | 5 | SEC filing |
| Nov 10, 2014 | Initial | $538,049 | No comparison | 12 | SEC filing |
| Oct 20, 2014 | Initial | $525,800 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $19.4K
- Finders' fees
- $0
- Form D file number
- 021-282836
Total sold in the US was USD$369,667 (based on the conversion of Canadian dollars to USD at an exchange rate of CDN$1.00=USD$0.7622, the Bank of Canada noon exchange rate on 12/13/16). An additional USD$41,551,333 was sold outside of the US under Reg. S.
Canadian dollars converted to US dollars at an exchange rate of CDN$1.00 = USD$0.7622 (the Bank of Canada noon exchange rate on 12/13/16).
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Canaccord Genuity Corp. | None | Canaccord Genuity Inc. · CRD 1020 |
| Dundee Securities Ltd. | None | |
| Beacon Securities Limited | None | |
| Cormark Securities Inc. | None |
Source: Form D, filed Mar 17, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Bechtel | Director |
| Chris Bechtel | Director |
| Navdeep Dhaliwal | Director, Executive |
| John Fowler | Director, Executive |
| Cailin Gehlsen | Executive |
| Peter Herburger | Executive |
| Tatiana Kovaleva | Executive |
| Michael La Brier | Director |
| Allan Levien | Director |
| Chuck Rifici | Director |
| David Stadnyk | Director, Executive |
| George Tsafalas | Director |
| Scott Walters | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
202 20 De Boers Drive
Toronto, A6, M3J 0H1
Toronto, A6, M3J 0H1